OKYO Pharma Limited Listing of Trial on the ClinicalTrials.gov Website
16 Marzo 2023 - 8:01AM
RNS Non-Regulatory
TIDMOKYO
OKYO Pharma Limited
16 March 2023
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry
Eye Disease is now listed on the ClinicalTrials.gov Public
Website.
London and New York, NY, March 16, 2023 - OKYO Pharma Limited
(LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused
bio-pharmaceutical company which is developing OK-101 to treat dry
eye disease (DED) to address the significant unmet need in this
multi-billion-dollar market, today announced that its planned trial
evaluating the efficacy and safety of OK-101 in subjects with DED
has been posted on the ClinicalTrials.gov public website
(ClinicalTrials.gov Identifier: NCT05759208). ClinicalTrials.gov is
a Web-based resource that provides patients, their family members,
health care professionals, researchers, and the public with easy
access to information on publicly and privately supported clinical
studies on a wide range of diseases and conditions.
OKYO is presently in the process of activating those clinical
sites planned for the trial, and preparing the clinical trial drug
product OK-101 for shipment to those sites involved in the
double-blind, placebo-controlled trial, along with other activities
needed for initiating the trial. OKYO is now anticipating the
first-patient first-visit initiation of the trial in early Q2 2023
and still looking to release top-line data from this trial in Q4
2023.
"We are excited to be very close now to moving this drug into
its first clinical trial and believe that OK-101 can provide a new
way to treat DED patients who are presently not well-served by
currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO
Pharma Ltd.
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences
company admitted to listing on NASDAQ and on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain. For further information, please visit www.okyopharma.com.
About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide (MAP)
technology to produce a novel long-acting drug candidate for
treating dry eye disease. OK-101 has been shown to produce
anti-inflammatory and pain-reducing activities in mouse models of
dry eye disease and corneal neuropathic pain; and is designed to
combat washout through the inclusion of the lipid 'anchor'
contained in the candidate drug molecule to enhance the residence
time of OK-101 within the ocular environment.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please visit the Company's website at
www.okyopharma.com
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
Gary S. Jacob, Chief Executive +44 (0)20 7495
OKYO Pharma Limited Officer 2379
+44 (0)20 7495
Investor Relations Paul Spencer 2379
Optiva Securities
Limited +44 (0)20 3981
(Broker) Robert Emmet 4173
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKDSFSKDEFA
(END) Dow Jones Newswires
March 16, 2023 03:01 ET (07:01 GMT)
Grafico Azioni Okyo Pharma (LSE:OKYO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Okyo Pharma (LSE:OKYO)
Storico
Da Set 2023 a Set 2024